Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331192

Institution ID

3331192

Institution full name and acronym

University Hospital Vall d’Hebron (HUVH)

Institution countries

Spain

Type of institution

Educational Institution
Hospital/Clinic/Other health care facility

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

A post-authorization study to assess the safety and efficacy of Fanhdi (Double-inactivated human anti-hemophilic factor) in subjects with Von Willebrand disease (PostAuthorization Study with Fanhdi in VWD patient)
Alofisel-5003: An Observational Post-Marketing Registry on the Effectiveness and Safety of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistulas (INSPIRE)
DEVELOPMENT AND VALIDATION OF A SHORTENED VERSION OF THE SPANISH QUALITY OF LIFE QUESTIONNAIRE FOR INFLAMMATORY BOWEL DISEASE
ESTUDIO AUXOGROWTH - Estudio Exploratorio para la Utilización del Programa de Crecimiento AuxoLog en Pacientes con Déficit de Hormona de Crecimiento tratados con Hormona de Crecimiento Recombinante Biosimilar
Evaluation of COPD Control and its Clinical Implications in a Real-Life UK Primary Care Population
id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe
id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe
International Observational, Study to Evaluate the Benefit/Risk of Vandetanib (Caprelsa™) 300 mg in RET Mutation Negative and RET Mutation Positive Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (Caprelsa 104)
Non-interventional, cross-sectional, multicenter study to describe the exacerbations profile of COPD patients Treated with ICS in a real-life primary care population in Spain. OPTI Study
Prospective cohort of COVID-19 cases diagnosed in Vall d'Hebron Hospital, Barcelona, during the 2020 outbreak.
Real-world characteristics, management and outcomes of subjects screened or diagnosed with COVID-19 in Spain (COVID-19 REAL)
RISK OF AGRANULOCYTOSIS ASSOCIATED WITH THE USE OF DRUGS
Risk of lactic acidosis associated with metformin use in patients with type 2 diabetes and moderate-severe chronic kidney disease: a case-control study (ALIMAR-C2)
Study of a prospective cohort of health professionals with coronavirus infection (COVID-19) treated with hydroxychloroquine (VDH-HID-2020-02)
Study on the use of non-specific immunoglobulins in patients treated at Vall d'Hebron University Hospital, Bellvitge Hospital and Germans Trias i Pujol Hospital, collected in the CatSalut's patient and treatment registry (RPT). (VDH-IGG-2021-03)
Validation of the Concept of COPD Control in Clinical Practice